JP2024535431A5 - - Google Patents
Info
- Publication number
- JP2024535431A5 JP2024535431A5 JP2024519055A JP2024519055A JP2024535431A5 JP 2024535431 A5 JP2024535431 A5 JP 2024535431A5 JP 2024519055 A JP2024519055 A JP 2024519055A JP 2024519055 A JP2024519055 A JP 2024519055A JP 2024535431 A5 JP2024535431 A5 JP 2024535431A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- scaffold
- sequence number
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163249553P | 2021-09-28 | 2021-09-28 | |
| US63/249,553 | 2021-09-28 | ||
| US202263375282P | 2022-09-12 | 2022-09-12 | |
| US63/375,282 | 2022-09-12 | ||
| PCT/US2022/077182 WO2023056297A1 (en) | 2021-09-28 | 2022-09-28 | Cd40l-specific tn3-derived scaffolds for the treatment and prevention of sjogren's syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024535431A JP2024535431A (ja) | 2024-09-30 |
| JP2024535431A5 true JP2024535431A5 (cg-RX-API-DMAC7.html) | 2025-10-07 |
Family
ID=84360925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024519055A Pending JP2024535431A (ja) | 2021-09-28 | 2022-09-28 | シェーグレン症候群の治療及び予防におけるcd40l特異的tn3由来足場 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20240383991A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4408455A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024535431A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240101563A9 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022358509A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3230926A1 (cg-RX-API-DMAC7.html) |
| CL (2) | CL2024000881A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL311710A (cg-RX-API-DMAC7.html) |
| MA (1) | MA65537A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024003954A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023056297A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20260217842A1 (en) * | 2023-01-13 | 2026-07-30 | Viela Bio, Inc. | Cd40l-specific tn3-derived scaffolds for the treatment and prevention of sjögren's syndrome |
| KR20250162587A (ko) * | 2023-03-28 | 2025-11-18 | 비엘라 바이오, 인크. | 쇼그렌 증후군의 치료 및 예방을 위한 cd40l 특이적 tn3 유래 스캐폴드 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3704158A1 (en) * | 2017-11-03 | 2020-09-09 | Novartis AG | Anti-cd40 antibodies for use in treatment of sjögren's syndrome |
| KR102919125B1 (ko) * | 2018-09-26 | 2026-01-27 | 비엘라 바이오, 인크. | Cd40l 길항제 및 이의 용도 |
-
2022
- 2022-09-28 AU AU2022358509A patent/AU2022358509A1/en active Pending
- 2022-09-28 MA MA65537A patent/MA65537A1/fr unknown
- 2022-09-28 CA CA3230926A patent/CA3230926A1/en active Pending
- 2022-09-28 MX MX2024003954A patent/MX2024003954A/es unknown
- 2022-09-28 KR KR1020247013785A patent/KR20240101563A9/ko active Pending
- 2022-09-28 EP EP22809606.1A patent/EP4408455A1/en active Pending
- 2022-09-28 JP JP2024519055A patent/JP2024535431A/ja active Pending
- 2022-09-28 IL IL311710A patent/IL311710A/en unknown
- 2022-09-28 WO PCT/US2022/077182 patent/WO2023056297A1/en not_active Ceased
-
2024
- 2024-03-21 US US18/612,452 patent/US20240383991A1/en active Pending
- 2024-03-26 CL CL2024000881A patent/CL2024000881A1/es unknown
-
2025
- 2025-03-03 CL CL2025000581A patent/CL2025000581A1/es unknown
- 2025-09-09 US US19/323,227 patent/US20260070997A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023052458A5 (cg-RX-API-DMAC7.html) | ||
| JP2022538237A5 (cg-RX-API-DMAC7.html) | ||
| HUP0301444A2 (hu) | Ribavirin és pegilezett alfa-interferon alkalmazása HCV fertőzés kezelésére szolgáló gyógyszerkészítmény előállítására | |
| WO1998005350A1 (en) | Materials and methods for treatment of plaquing diseases | |
| CN116390712A (zh) | 治疗偏头痛 | |
| CN101878037A (zh) | 能够中和乙型肝炎病毒的人抗体在预防或治疗乙型肝炎病毒感染中的用途 | |
| EP0230574A2 (en) | Pharmaceutical compositions against infections caused by LAV/HTLV III virus and the use thereof | |
| JP2023531682A (ja) | D型肝炎ウイルス感染の処置のための組成物および方法 | |
| EP4584295A1 (en) | Methods of treating chronic inflammatory demyelinating polyneuropathy using anti-fcrn antibodies | |
| JPH11501310A (ja) | レトロウイルスの調節タンパク質から誘導された無毒の免疫原、抗体、製造方法およびそれらを含んでなる医薬組成物 | |
| KR20110053327A (ko) | 텔라프레비르 투여 방식 | |
| JP2022514561A5 (cg-RX-API-DMAC7.html) | ||
| TW202417015A (zh) | 以非妥西蘭治療血友病 | |
| AU2021382954B2 (en) | Pharmaceutical composition, pharmaceutical combined formulation, and combined formulation kit for prevention or treatment of chronic hepatitis b, each comprising, as active ingredient, oral antiviral agent and therapeutic vaccine including lipopeptide and poly(i:c) adjuvant | |
| JP2024540294A5 (cg-RX-API-DMAC7.html) | ||
| JP2022513438A5 (cg-RX-API-DMAC7.html) | ||
| CN119923262A (zh) | 在儿科患者中用卡替拉韦和利匹韦林治疗hiv的方法 | |
| JP2000007578A (ja) | C型肝炎ウイルスの陰性化のための投薬システム | |
| JP2770911B2 (ja) | 抗ウイルス医薬組成物 | |
| CN101282741A (zh) | 治疗或预防缺血性再灌注损伤或多器官衰竭的方法 | |
| JP7619659B2 (ja) | コロナウイルス感染症を治療又は予防する方法及び組成物 | |
| JP2002500175A (ja) | ヒト免疫不全ウイルスに対して使用する多分枝ペプチド構築物含有リポソーム | |
| Longhurst et al. | In vivo CRISPR/Cas9 editing of KLKB1 in patients with HAE | |
| AU2025205863A1 (en) | Lutikizumab for use in a treatment of hidradenitis suppurativa | |
| JP2006515011A (ja) | Hcv併用療法 |